Clinical Trial Update: Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BTX 1204 for safety, tolerability, and efficacy in moderate atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• BTX 1204

Snippet

Sponsor: Botanix Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2022-09-27